FOLLITROPIN ALFA

Information current as at: 1 June 2026

Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Ovaleap®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
Theramex Australia Pty Ltd
Condition/indication:
(therapeutic use)
  • Assisted Reproductive Technology; Anovulatory infertility; Infertility.
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
Change to listing (Category 3-4)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
July 2021 PBAC meeting
Opportunity for consumer comment:
Open 21/03/2021 and close 26/05/2021 (see PBS Website)
PBAC meeting:
Held on 07/07/2021
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
30/08/2021
Lodgement of required documentation:
07/09/2021
Acceptance of complete documentation:
Accepted
Agreement to listing arrangements:
Commenced on 17/09/2021
Status:
Finalised
Government processes:
Commenced on 13/10/2021
Medicine listed on the PBS:
01/12/2021 (see PBS schedule)

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information

Case ID
a352
Page last updated
31 March 2026
v.9.19